Phathom Pharmaceuticals Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
371
- Stock Symbol
-
PHAT
- Share Price
-
$6.06
- (As of Friday Closing)
Phathom Pharmaceuticals General Information
Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Contact Information
Website
www.phathompharma.comCorporate Office
- 100 Campus Drive
- Suite 102
- Florham Park, NJ 07932
- United States
Corporate Office
- 100 Campus Drive
- Suite 102
- Florham Park, NJ 07932
- United States
Phathom Pharmaceuticals Stock Performance
As of 13-Nov-2026, Phathom Pharmaceuticals’s stock price is $6.06. Its current market cap is $493M with 81.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.06 | $6.23 | $5.01 - $18.31 | $493M | 81.3M | 1.43M | -$1.03 |
Phathom Pharmaceuticals Financials Summary
As of 30-Sep-2026, Phathom Pharmaceuticals has a trailing 12-month revenue of $275M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 575,211 | 1,254,838 | 396,955 | 409,646 |
| Revenue | 274,881 | 175,110 | 55,252 | 682 |
| EBITDA | (25,868) | (159,543) | (276,675) | (166,900) |
| Net Income | (82,996) | (221,247) | (334,326) | (201,592) |
| Total Assets | 345,020 | 259,149 | 378,318 | 413,842 |
| Total Debt | 167,957 | 211,800 | 201,910 | 139,030 |
Phathom Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Phathom Pharmaceuticals Comparisons
Industry
Financing
Details
Phathom Pharmaceuticals Competitors (31)
One of Phathom Pharmaceuticals’s 31 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Phathom Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Phathom Pharmaceuticals Patents
Phathom Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4780455-A1 | Method for preparing vonoprazan with reduced nitrosamine | Pending | 18-Sep-2023 | ||
| US-20260199243-A1 | Method for preparing vonoprazan with reduced nitrosamine | Pending | 18-Sep-2023 | ||
| WO-2025064381-A1 | Method for preparing vonoprazan with reduced nitrosamine | Inactive | 18-Sep-2023 | A61K9/2013 |
Phathom Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Phathom Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.08 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Phathom Pharmaceuticals FAQs
-
When was Phathom Pharmaceuticals founded?
Phathom Pharmaceuticals was founded in 2018.
-
Where is Phathom Pharmaceuticals headquartered?
Phathom Pharmaceuticals is headquartered in Florham Park, NJ.
-
What is the size of Phathom Pharmaceuticals?
Phathom Pharmaceuticals has 371 total employees.
-
What industry is Phathom Pharmaceuticals in?
Phathom Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Phathom Pharmaceuticals a private or public company?
Phathom Pharmaceuticals is a Public company.
-
What is Phathom Pharmaceuticals’s stock symbol?
The ticker symbol for Phathom Pharmaceuticals is PHAT.
-
What is the current stock price of Phathom Pharmaceuticals?
As of 13-Nov-2026 the stock price of Phathom Pharmaceuticals is $6.06.
-
What is the current market cap of Phathom Pharmaceuticals?
The current market capitalization of Phathom Pharmaceuticals is $493M.
-
What is Phathom Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Phathom Pharmaceuticals is $275M.
-
Who are Phathom Pharmaceuticals’s competitors?
Crinetics Pharmaceuticals, Ardelyx, Aclaris Therapeutics, Aldeyra Therapeutics, and Rein Therapeutics are some of the 31 competitors of Phathom Pharmaceuticals.
-
What is Phathom Pharmaceuticals’s annual earnings per share (EPS)?
Phathom Pharmaceuticals’s EPS for 12 months was -$1.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
